Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rgnull RI P-DTR mice engrafted with human islets

Diabetes, Metabolic Syndrome and Obesity

Volumn 8, Issue , 2015, Pages 387-398

  Yang, Chaoxing ^a   Loehn, Matthias ^b   Jurczyk, Agata ^a   Przewozniak, Natalia ^a   Leehy, Linda ^a   Herrera, Pedro L ^c   Shultz, Leonard D ^d   Greiner, Dale L ^a   Harlan, David M ^a   Bortell, Rita ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d JACKSON LABORATORY   (United States)

Author keywords

Beta cells; GLP 1 receptor agonist; Glucose tolerance tests; Human islet transplant; Lixisenatide; Plasma insulin

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; LIXISENATIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; MIDDLE AGED; MOUSE; NOD SCID MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL;

EID: 84940048643     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S87253     Document Type: Article

References (39)

1. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003; 17(2): 161-171.
2. Garber AJ. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care. 2011; 34(Suppl 2): S258-S263.
3. Kwon DY, Kim YS, Ahn IS, et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci. 2009; 111(4): 361-371.
4. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004; 145(6): 2653-2659.
5. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev. 2003; 19(2): 115-123.
6. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol. 2000; 143(6): 717-725.
7. Yamane S, Hamamoto Y, Harashima S, et al. GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated beta-cell damage in Akita mice. J Diabetes Investig. 2011; 2(2): 104-110.
8. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006; 4(5): 391-406.
9. Tsunekawa S, Yamamoto N, Tsukamoto K, et al. Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J Endocrinol. 2007; 193(1): 65-74.
10. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90(11): 5991-5997.
11. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30(6): 1608-1610.
12. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87(3): 1239-1246.
13. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009; 32(12): 2251-2257.
14. Sarkar G, Alattar M, Brown RJ, et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014; 37(3): 666-670.
15. Elkinson S, Keating GM. Lixisenatide: first global approval. Drugs. 2013; 73(4): 383-391.
16. Petersen AB, Knop FK, Christensen M. Lixisenatide for the treatment of type 2 diabetes. Drugs Today (Barc). 2013; 49(9): 537-553.
17. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009; 12(8): 503-513.
18. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010; 164(2-3): 58-64.
19. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012; 35(6): 1225-1231.
20. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013; 30(2): 81-101.
21. Petersen AB, Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013; 6: 217-231.
22. Ahren B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; 16(9): 861-868.
23. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8(12): 728-742.
24. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008; 294(5): E846-E852.
25. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008; 151(1-3): 123-129.
26. Tews D, Werner U, Eckel J. Enhanced protection against cytokine-and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res. 2008; 40(3): 172-180.
27. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007; 7(2): 118-130.
28. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10): 6477-6489.
29. Jurczyk A, Diiorio P, Brostowin D, et al. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rgamma(null) mice treated with alogliptin. Diabetes Metab Syndr Obes. 2013; 6: 493-499.
30. Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab. 2010; 95(10): E234-E239.
31. Levitt HE, Cyphert TJ, Pascoe JL, et al. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia. 2011; 54(3): 572-582.
32. Diiorio P, Jurczyk A, Yang C, et al. Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rgammanull Ins2Akita mice. Pancreas. 2011; 40(7): 1147-1149.
33. Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem. 2005; 53(9): 1087-1097.
34. Becker RH, Stechl J, Msihid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes-a study in both people with type 2 diabetes and healthy subjects. Diabetes Obes Metab. 2014; 16(9): 793-800.
35. Ratner RE, Rosenstock J, Boka G, Investigators DRIS. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010; 27(9): 1024-1032.
36. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003; 144(12): 5149-5158.
37. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short-and long-term hyperglycemia. Diabetes. 2002; 51(1): 66-72.
38. Davalli AM, Ogawa Y, Ricordi C, Scharp DW, Bonner-Weir S, Weir GC. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation. 1995; 59(6): 817-820.
39. Toyoda K, Okitsu T, Yamane S, et al. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun. 2008; 367(4): 793-798.